FINWIRES · TerminalLIVE
FINWIRES

奧本海默公司稱，儘管面臨成本壓力，Freshpet仍有望實現全年目標。

By

-- 奧本海默公司週四發布的一份報告稱，即使貨運成本不斷上漲，Freshpet (FRPT) 仍有望實現全年目標。 奧本海默認為，Freshpet第一季銷售額成長10.9%的華爾街預期存在上行空間，部分原因是其在好市多(COST)的分銷管道顯著擴張。 在成本和消費者支出前景更加不明朗的情況下，奧本海默預計Freshpet至少會重申其2026年全年業績指引，這可能為其今年晚些時候的業績超預期和業績上調奠定基礎。 報告指出，好市多的自有品牌Kirkland Signature是一個強大的競爭對手，但Freshpet更豐富的產品線和在好市多的顯著市場份額應該能夠使其保持穩健成長。 報告稱，受新競爭和寵物用品市場訊號不一的擔憂影響，投資者對Freshpet中長期前景的看法仍然喜憂參半。 第一季業績將於週三公佈。在消費必需品產業面臨困境的背景下，Freshpet 仍然是 Oppenheimer 的首選小型股。 Oppenheimer 對 Freshpet 股票的評級為“跑贏大盤”，目標價為 80 美元。

Price: $66.19, Change: $+0.05, Percent Change: +0.08%

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM